MADD Expression in Lung Adenocarcinoma and Its Impact on Proliferation and Apoptosis of Lung Adenocarcinoma Cells

Bo Ye,Fangming Zhong,Guocan Yu,Haizhou Lou,Jian Hu
DOI: https://doi.org/10.2174/1386207322666190404151437
2019-01-01
Combinatorial Chemistry & High Throughput Screening
Abstract:Objective: This study investigated the expression of MAPK-activating death domaincontaining protein (MADD) in lung adenocarcinoma and its impact on lung adenocarcinoma SPCA- 1 cell proliferation and apoptosis. Methods: Clinicopathological lung specimens were collected. MADD expression levels in normal human lung and human lung adenocarcinoma tissues were detected by immunohistochemistry. Lung adenocarcinoma SPC-A-1 cells were cultured, and IG20 gene expression in the SPC-A-1 cells was detected using reverse-transcription PCR. SPC-A-1 cells were transfected with a plasmid carrying the MADD gene and a lentiviral vector capable of silencing MADD expression. CCK-8 assay, western blot and flow cytometry were performed to detect MADD expression, proliferation and apoptosis in the SPC-A-1 cells. Results: MADD expression levels in the lung adenocarcinoma tissue were significantly higher than those in the normal lung tissue and lung squamous carcinoma cells. MADD can be expressed in lung adenocarcinoma SPC-A-1 cells. High MADD expression can inhibit SPC-A-1 cell apoptosis and enhance SPC-A-1 cell proliferative activity, while silencing MADD expression can promote apoptosis and reduce SPC-A-1 cell proliferation. Conclusion: MADD expression is significantly upregulated in lung adenocarcinoma tissue. MADD can promote lung adenocarcinoma cell growth by inhibiting apoptosis. This study may improve lung adenocarcinoma levels in patients and, thus, is worthy of clinical promotion.
What problem does this paper attempt to address?